id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-2107-0009,FDA,FDA-2020-D-2107,"Cross Labeling Oncology Drugs in Combination Regimens; Guidance for
Industry; Availability",Notice,Notice of Availability,2022-11-03T04:00:00Z,2022,11,2022-11-03T04:00:00Z,,2022-11-03T12:37:22Z,2022-23866,0,0,09000064854812db
FDA-2020-D-2107-0010,FDA,FDA-2020-D-2107,Cross Labeling Oncology Drugs in Combination Regimens; Guidance for Industry;  Final Guidance,Other,Guidance,2022-11-03T04:00:00Z,2022,11,2022-11-03T04:00:00Z,,2024-11-07T00:44:07Z,,1,0,0900006485481576
FDA-2020-D-2107-0007,FDA,FDA-2020-D-2107,Cross Labeling Oncology Drugs in Combination RegimensGuidance for Industry,Other,Guidance,2020-11-20T05:00:00Z,2020,11,2021-02-18T05:00:00Z,,2022-11-03T12:46:10Z,,0,0,090000648496d16b
FDA-2020-D-2107-0001,FDA,FDA-2020-D-2107,"Cross Labeling Oncology Drugs in Combination Drug Regimens; Draft
Guidance for Industry; Availability",Notice,Notice of Availability,2020-11-20T05:00:00Z,2020,11,2020-11-20T05:00:00Z,2021-01-20T04:59:59Z,2021-01-20T02:02:52Z,2020-25737,0,0,090000648496ac8d